We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

25 hedge funds and large institutions have $19.3M invested in NeuBase Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

21% more capital invested

Capital invested by funds: $16M → $19.3M (+$3.31M)

14% more funds holding

Funds holding: 22 → 25 (+3)

Holders
25
Holders Change
+3
Holders Change %
+13.64%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
5
Reduced
3
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$2.46M
2
Squarepoint
Squarepoint
New York
+$417K
3
Renaissance Technologies
Renaissance Technologies
New York
+$187K
4
PPCM
Pillar Pacific Capital Management
California
+$131K
5
Jane Street
Jane Street
New York
+$112K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$99K
2
Citadel Advisors
Citadel Advisors
Florida
-$85K
3
FAIM
Financial Advocates Investment Management
Washington
-$72K
4
Deutsche Bank
Deutsche Bank
Germany
-$38K
5
Millennium Management
Millennium Management
New York
-$34.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$11M – – –
Renaissance Technologies
2
Renaissance Technologies
New York
$2.72M +$187K +1,414 +8%
O
3
OrbiMed
New York
$2.64M +$2.46M +18,556 New
EI
4
EAM Investors
California
$741K +$27.5K +208 +4%
Squarepoint
5
Squarepoint
New York
$449K +$417K +3,153 New
BlackRock
6
BlackRock
New York
$371K – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$293K – – –
Millennium Management
8
Millennium Management
New York
$167K -$34.5K -261 -18%
PPCM
9
Pillar Pacific Capital Management
California
$141K +$131K +990 New
Jane Street
10
Jane Street
New York
$121K +$112K +850 New
Geode Capital Management
11
Geode Capital Management
Massachusetts
$115K – – –
Qube Research & Technologies (QRT)
12
Qube Research & Technologies (QRT)
United Kingdom
$87K – – –
HWA
13
Heritage Wealth Advisors
Virginia
$86.2K – – –
ECM
14
ExodusPoint Capital Management
New York
$84K -$2.78K -21 -3%
FIA
15
FNY Investment Advisers
New York
$80K +$70.3K +531 +1,609%
Morgan Stanley
16
Morgan Stanley
New York
$68K +$11.5K +87 +22%
Bank of America
17
Bank of America
North Carolina
$65K +$60.3K +456 New
Acadian Asset Management
18
Acadian Asset Management
Massachusetts
$54K +$50.1K +379 New
DWA
19
Dorsey Wright & Associates
California
$11K +$10.5K +79 New
Citigroup
20
Citigroup
New York
$7K +$6.48K +49 New
SSB
21
Sandy Spring Bank
Maryland
$4K – – –
Wells Fargo
22
Wells Fargo
California
$4K +$4.23K +32 New
Osaic Holdings
23
Osaic Holdings
Arizona
$3K +$3.04K +23 New
CLOS
24
Compagnie Lombard Odier SCmA
Switzerland
$2K +$529 +4 +40%
UBS Group
25
UBS Group
Switzerland
$1K -$1.32K -10 -59%
1
2

NBSE Hedge Fund Activity: Q1 2020 in Review

25 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2020, worth a combined $19.3M — up 21% from $16M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new NBSE positions and 6 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $2.46M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $99K sold.

  • 25 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2020, up from 22 in Q4 2019.
  • Funds reported $19.3M of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2020, up 21% quarter-over-quarter.
  • 10 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2020 and 6 closed out, a net change of +4 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2020 was OrbiMed, an estimated $2.46M added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2020 was JP Morgan Chase, an estimated $99K sold.

Based on aggregated 13F filings for Q1 2020.